Mark Rasmus, MD
Pulmonary Disease · Boise, IDNPI 1528106309
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $27,524 of the $43,523 with a category attached, or 63.2%. 18 manufacturers reported payments, led by Harmony Biosciences LLC at 37.8% of the total. Among pulmonary disease clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $201.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$16K
- Axsome Therapeutics, Inc.$13K
- Boehringer Ingelheim$7K
- Fisher & Paykel Healthcare Inc$2K
- Inspire Medical Systems, Inc.$2K
- Jazz Pharmaceuticals Inc.$2K
- plus $2K from 12 others
Across 65 payments — averaging $732.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$48K
What the payments were for
- Consulting fees$8,66120%
- Speaking & faculty fees$27,52463%
- Travel & lodging$1,3003%
- Food & beverage$5,34612%
- Education$6922%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 69 | $16,443 |
| Axsome Therapeutics, Inc. | 24 | $12,729 |
| Boehringer Ingelheim | 8 | $6,967 |
| Fisher & Paykel Healthcare Inc | 21 | $2,330 |
| Inspire Medical Systems, Inc. | 6 | $1,783 |
| Jazz Pharmaceuticals Inc. | 35 | $1,737 |
| Philips North America LLC | 12 | $465 |
| Avadel CNS Pharmaceuticals, LLC | 11 | $378 |
| Eisai Inc. | 9 | $165 |
| GSK | 4 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $120 |
| Arbor Pharmaceuticals, Inc. | 6 | $94 |
| 3b Medical, Inc. | 3 | $37 |
| Vanda Pharmaceuticals Inc. | 2 | $37 |
| Itamar Medical Inc | 1 | $30 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Resmed Corp | 1 | $29 |
| Viatris Specialty LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Wakix$15,542
- SUNOSI$12,410
- FISHER & PAYKEL HEALTHCARE$9,283
- Inspire Upper Airway Stimulation System$1,674
- XYWAV$266
- XYREM$150
- Sleep Therapy Modems$126
- LUMRYZ$126
- (1944) PRI Cpap$109
How this compares
$43,523 in reported general payments places this provider in the 95th percentile of 57 pulmonary disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $27,321 |
| SunosiSolriamfetol Hcl | 15 | $22,773 |
| Armodafinil | 47 | $6,273 |
| Gabapentin | 155 | $3,043 |
| Modafinil | 11 | $533 |
| Ropinirole Hcl | 23 | $526 |
| Trazodone Hcl | 111 | $504 |
| Zolpidem Tartrate | 55 | $490 |
| Methadone Hcl | 24 | $310 |
| Clonazepam | 25 | $265 |
| Azithromycin | 11 | $236 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $131 | $27,32131 claims |
| Axsome Therapeutics, Inc.Sunosi | $12,729 | $22,77315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 57 pulmonary disease providers in Idaho.
Other pulmonary disease in Boise
- Norman EastBoise$11K
- Derek LindermanBoise$7K
- Janat O DonnellBoise$590
- Zahra MathuraBoise$541
- Joshua HolwegerBoise$429
- Rory RamseyBoise$418
- Cedric MunozBoise$303
- Kathleen SutherlandBoise$224
- Lyndsey TurbowBoise$195
- Ryan BiblerBoise$61
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.